This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
To gain insight into the motivations, steps and experiences involved in an academia to industry — or vice versa — transition, Xtalks spoke to several leading scientists and entrepreneurs in pharma and biotech who successfully transitioned from academic positions to leadership roles in industry settings. A life-changing moment came for Dr.
After raising $125m in 2021 to redevelop the facility, more recently Touchlight secured an additional $17.3m (£14m) from the UK government’s LifeSciences Innovative Manufacturing Fund to accelerate its expansion plans and scale-up equipment. Free Report How is the Biopharmaceutical industry evolving?
We’ve got so many great lifescience assets in the UK, but there are still some gaps – manufacturing capacity being one of them.”. “We We had companies collaborating to develop laboratories. We had companies sourcing consumables for testing machines. Strength in the second wave. We’re very grateful for that.
In recent years, CRISPR has also been effectively applied to reduce or eliminate persistent viral infections in vitro and in animal models, raising hope for its use in treating latent and chronic viral infections. Related: Biotech IPOs in 2024: Navigating the New Wave of Innovation 1.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content